Anti-Tau 抗体 [TAU-5] - BSA and Azide free

• WB

Lab

Western blot - Anti-Tau antibody [TAU-5] - BSA and Azide free (AB80579)

Overnight at 4°C. Binding at expected molecular weights consistent with Tau protein across the various species.

All lanes:

Western blot - Anti-Tau antibody [TAU-5] - BSA and Azide free (ab80579) at 1 µg/mL

Lane 1:

Human Brain Tissue Lysate at 40 µg

Lane 2:

Mouse Brain Tissue Lysate at 40 µg

Lane 3:

Rat Brain Tissue Lysate at 20 µg

Secondary

Lanes 1 - 3:

Western blot - Goat anti-Mouse IgG H&L (IRDye® 800CW) preadsorbed (<a href='/products/secondary-antibodies/goat-mouse-igg-h-l-irdye-800cw-preadsorbed-ab216772'>ab216772</a>) at 1/20000 dilution

Lanes 1 - 3:

Western blot - Goat Anti-Rabbit IgG H&L (IRDye® 680RD) preadsorbed (<a href='/products/secondary-antibodies/goat-rabbit-igg-h-l-irdye-680rd-preadsorbed-ab216777'>ab216777</a>) at 1/20000 dilution

false

• ICC/IF

Lab

Immunocytochemistry/ Immunofluorescence - Anti-Tau antibody [TAU-5] - BSA and Azide free (AB80579)

Cells incubated overnight at 4°C. The cells were fixed with 4% paraformaldehyde (10 min), permeabilized with 0.1% PBS-Tween for 5 minutes and then blocked with 1% BSA/10% normal goat serum/0.3M glycine in 0.1%PBS-Tween for 1h. Nuclear DNA was labelled with DAPI (shown in blue). Image was acquired with a high-content analyser (Operetta CLS, Perkin Elmer) and a maximum intensity projection of confocal sections is shown.

• WB

CiteAb

Western blot - Anti-Tau antibody [TAU-5] - BSA and Azide free (AB80579)

Western Blotting using Anti-Tau antibody [TAU-5] - BSA and Azide free, ab80579. Publication image from Zhang, P. et al., 2020, Microbiome, 33008466. Legend direct from paper.

Long-term β-glucan supplementation improved PTP1B-IRS-pAKT-pGSK3β-pTau and synapse in the hippocampus of HFFD-induced obese mice. a The protein level of PTP1B in the hippocampus (n = 6). b–d Protein levels of p-IRS-1/IRS-1, p-Akt/Akt, and p-GSK3β/GSK3β (n = 6). e The protein level of p-Tau/Tau in the hippocampus (n = 4–6). f The ultrastructure of synapses on the electron micrograph in the hippocampus CA1 region of mice fed with different diets (scale bar 500 nm). The enlarged images of the second row were from the first row in the area indicated with a dotted line box (scale bar 250 nm). g and h Image analysis of the thickness of PSD and the width of the synaptic cleft (n = 3). PSD, postsynaptic density; SC, synaptic cleft; SV, synaptic vesicle. i and j The protein levels of SYN and PSD95. Values are mean ± SEM. *p < 0.05 vs. control (Con). #p < 0.05 vs. high-fat and fiber-deficient (HFFD)

false

• WB

CiteAb

Western blot - Anti-Tau antibody [TAU-5] - BSA and Azide free (AB80579)

Tau western blotting using Anti-Tau antibody [TAU-5] - BSA and Azide free ab80579. Publication image and figure legend from Terron, H. M., Parikh, S. J., et al., 2024, ' Alzheimers Res Ther, Pubmed 38575959.

Inhibition of CatD slows the catabolism of tau in vitro and in cultured cells. (A) Representative Coomassie blue-stained polyacrylamide gel loaded with recombinant human tau (rTau) incubated for the indicated times with recombinant human CatD (5 nM) in the absence or presence of equal concentrations (1 µm) of Aβ40 or Aβ42. (B) Quantification of rTau levels as a function of time in 4 independent experiments. Note how rTau catabolism is unaffected by Aβ40 but markedly slowed by Aβ42, a potent competitive inhibitor of CatD. Data are mean ± SEM; n = 4. (C) Overview of the experimental approach used to quantify hTau catabolism in "Tet-Off" cultured neuroblastoma cells (see main text). (D) Representative western blot showing hTau levels (stained with antibody P44) at different time points after cessation of hTau expression in the absence or presence of the CatD inhibitor, pepstatin A (PepA; 1 µm). (E) Quantitation of hTau levels as a function of time from 6 independent experiments. Note the marked increase in the half-life of hTau in the presence of PepA (0.98 days; 95% CI 0.80 to 1.25) relative to DMSO-treated controls (0.51 days; 95% CI 0.429 to 0.627; P = 0.0012). Data are mean ± SEM, n = 6

false

• WB

CiteAb

Western blot - Anti-Tau antibody [TAU-5] - BSA and Azide free (AB80579)

Tau western blotting using Anti-Tau antibody [TAU-5] - BSA and Azide free ab80579. Publication image and figure legend from Ye, J., Yin, Y., et al., 2020, Aging Cell, Pubmed 31668016.

Overexpressing hTau in mouse hippocampal CA3 neurons induces memory deficits with PKA inhibition and CREB/GluA1 dephosphorylation. (a-c) AAV-syn-hTau-EGFP was infused into the hippocampal CA3 subset of 2-month-old mice, and after one month, the expression of hTau in the infused site (scale bar : left, 250 μm; right, 50 μm) was confirmed by direct fluorescence imaging (a), and western blotting (110 kDa) using Tau5 (b and c; n = 6 mice per group). (d-f) Overexpressing hTau induces memory deficit measured by novel object recognition (NOR) test. The recognition index measured at the first training day (d), and the reduced recognition index (e) and the discrimination index (f) recorded at 24 hr after training (n = 15 mice per group) were analyzed. (g-k) Overexpressing hTau induces spatial learning and memory deficits measured by Morris water maze (MWM). The spatial learning deficit was shown by the increased latency to find the hidden platform during 6 days of training (g), while the memory deficit was shown by the increased latency to reach the platform site (h), decreased target platform crossings (i), and decreased time spent in the target zone (j) measured at day 8 by removing the platform (n = 15 mice per group). The swimming speed was not changed (k). (l) Overexpressing hTau inhibits PKA activity measured by using a PKA activity assay kit. The injected hippocampal CA3 subsets were dissected, and the tissue extracts were used. (m, n) Overexpressing hTau reduced levels of pGluA1 and pCREB measured by western blotting (m) and the quantification (n); HT7 specifically reacts with human tau. Data were expressed as mean ± SEM, *p < < .05, **p < < .01 versus Vec, but *p < < .05 versus object A in (e)

false

• WB

CiteAb

Western blot - Anti-Tau antibody [TAU-5] - BSA and Azide free (AB80579)

Tau western blotting using Anti-Tau antibody [TAU-5] - BSA and Azide free ab80579. Publication image and figure legend from Do, C. B., Jaiswal, M. S., et al., 2022, , Sci Rep, Pubmed 36151253.

western blotting of SH-SY5Y cell extracts. GAPDH was used as a loading control. The expression of tau increased significantly after 24 h of NTP treatment. The expression of GAP43 showed no significant difference, while the expression of MAP2 decreased significantly after 3, 6, 24, and 48 h of NTP treatment. *Indicates p < 0.05, ** indicates p < 0.01.

false